Antiplatelet resistance in stroke

References

• Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation121(7), e46–e215 (2010).
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet367(9510), 606–617 (2006).
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA303(8), 754–762 (2010).
   PubMed Web of Science ®Google Scholar
• Michelson AD. Methods for the measurement of platelet function. Am. J. Cardiol.103(3 Suppl.), A20–A26 (2009).
   PubMed Web of Science ®Google Scholar
• Jeon SB, Song HS, Kim BJ et al. Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur. Neurol.64(1), 51–57 (2010).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, Uhry S, Alessi MC, Bonnet JL. Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder: shifting from antiplatelet resistance to bleeding risk assessment? Int. J. Cardiol.138(2), 212–213 (2010).
   PubMed Web of Science ®Google Scholar
• May AE, Geisler T, Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb. Haemost.99(3), 487–493 (2008).
   PubMed Web of Science ®Google Scholar
• Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. J. Cardiovasc. Pharmacol. Ther.14(3), 157–169 (2009).
   PubMed Web of Science ®Google Scholar
• Blais N, Pharand C, Lordkipanidze M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb. Haemost.102(2), 404–411 (2009).
   PubMed Web of Science ®Google Scholar
• Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart. J.28(14), 1702–1708 (2007).
   PubMed Web of Science ®Google Scholar
• Santilli F, Rocca B, De Cristofaro R et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin ‘resistance’. J. Am. Coll. Cardiol.53(8), 667–677 (2009).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Poyet R et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch. Cardiovasc. Dis.103(1), 39–45 (2010).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation115(25), 3156–3164 (2007).
   PubMed Web of Science ®Google Scholar
• Broadley AJ, Gapper P, Schmitt M, Frenneaux MP. Supine rest reduces platelet activation and aggregation. Platelets14(1), 3–7 (2003).
   PubMed Web of Science ®Google Scholar
• Smock KJ, Rodgers GM. Laboratory evaluation of aspirin responsiveness. Am. J. Hematol.85(5), 358–360 (2010).
   PubMed Web of Science ®Google Scholar
• Grotemeyer KH. The platelet-reactivity-test – a useful ‘by-product’ of the blood-sampling procedure? Thromb. Res.61(4), 423–431 (1991).
   PubMed Web of Science ®Google Scholar
• Dalby MC, Davidson SJ, Burman JF, Davies SW. Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser. Platelets11(6), 320–324 (2000).
   PubMed Web of Science ®Google Scholar
• Pamukcu B, Oflaz H, Acar RD et al. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation. J. Thromb. Thrombolysis20(1), 17–22 (2005).
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb. Res.124(5), 588–591 (2009).
   PubMed Web of Science ®Google Scholar
• Addad F, Chakroune T, Asma A et al. Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease. Thromb. Res.123(4), 640–643 (2009).
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J. Thromb. Haemost.8(1), 37–42 (2010).
   PubMed Web of Science ®Google Scholar
• Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. Semin. Thromb. Hemost.35(3), 295–306 (2009).
   PubMed Web of Science ®Google Scholar
• Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J. Thromb. Haemost.5(3), 507–511 (2007).
   PubMed Web of Science ®Google Scholar
• Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int. J. Obes. Relat. Metab. Disord.27(8), 907–911 (2003).
   PubMed Web of Science ®Google Scholar
• Ertugrul DT, Tutal E, Yildiz M et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.95(6), 2897–2901 (2010).
   PubMed Web of Science ®Google Scholar
• Hovens MM, Snoep JD, Groeneveld Y, Tamsma JT, Eikenboom JC, Huisman MV. High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes. J. Thromb. Haemost.5(7), 1562–1564 (2007).
   PubMed Web of Science ®Google Scholar
• Lee PY, Chen WH, Ng W et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am. J. Med.118(7), 723–727 (2005).
   PubMed Web of Science ®Google Scholar
• Karepov V, Tolpina G, Kuliczkowski W, Serebruany V. Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. Cerebrovasc. Dis.26(3), 272–276 (2008).
   PubMed Web of Science ®Google Scholar
• Bouman HJ, van Werkum JW, Hackeng CM, Verheugt FW, Ten Berg JM. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J. Thromb. Haemost.6(6), 1040–1042 (2008).
   PubMed Web of Science ®Google Scholar
• Mansour K, Taher AT, Musallam KM, Alam S. Aspirin resistance. Adv. Hematol.2009, 937352 (2009).
   PubMedGoogle Scholar
• Hedegaard SS, Hvas AM, Grove EL et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb. Res.124(1), 96–100 (2009).
   PubMed Web of Science ®Google Scholar
• Alberts MJ. Platelet function testing for aspirin resistance is reasonable to do: yes! Stroke41(10), 2400–2401 (2010).
   PubMed Web of Science ®Google Scholar
• Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets13(8), 493–497 (2002).
   PubMed Web of Science ®Google Scholar
• Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J. Neurol.50(1), 63–66 (2003).
   Google Scholar
• Linnemann B, Schwonberg J, Toennes SW, Mani H, Lindhoff-Last E. Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease. Atherosclerosis209(2), 504–509 (2010).
   PubMed Web of Science ®Google Scholar
• Lev EI. Aspirin resistance transient laboratory finding or important clinical entity? J. Coll. Cardiol.53(8), 678–680 (2009).
   PubMed Web of Science ®Google Scholar
• Helgason CM, Bolin KM, Hoff JA et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke25(12), 2331–2336 (1994).
   PubMed Web of Science ®Google Scholar
• Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J. Transl. Med.6, 46 (2008).
   PubMedGoogle Scholar
• Serebruany V, Cherala G, Williams C et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of ‘resistance’. Am. Heart J.158(6), 925–932 (2009).
   PubMed Web of Science ®Google Scholar
• Hamann GF, Weimar C, Glahn J, Busse O, Diener HC. Adherence to secondary stroke prevention strategies – results from the German Stroke Data Bank. Cerebrovasc. Dis.15(4), 282–288 (2003).
   PubMed Web of Science ®Google Scholar
• Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am. J. Cardiovasc. Drugs10(2), 125–141 (2010).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J et al. Aspirin noncompliance is the major cause of ‘aspirin resistance’ in patients undergoing coronary stenting. Am. Heart J.157(5), 889–893 (2009).
   PubMed Web of Science ®Google Scholar
• Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke37(8), 2153–2158 (2006).
   PubMed Web of Science ®Google Scholar
• Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation115(16), 2196–2207 (2007).
   PubMed Web of Science ®Google Scholar
• Schwertner HA, McGlasson D, Christopher M, Bush AC. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations. Thromb. Res.118(4), 529–534 (2006).
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med.345(25), 1809–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J. Am. Coll. Cardiol.51(3), 256–260 (2008).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. J. Am. Coll. Cardiol.54(13), 1149–1153 (2009).
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol.48(4), 475–484 (2008).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost.101(4), 714–719 (2009).
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ180(7), 713–718 (2009).
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA301(9), 937–944 (2009).
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet374(9694), 989–997 (2009).
   PubMed Web of Science ®Google Scholar
• Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation120(23), 2322–2329 (2009).
   PubMed Web of Science ®Google Scholar
• Lau WC, Waskell LA, Watkins PB et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation107(1), 32–37 (2003).
   PubMed Web of Science ®Google Scholar
• Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function – a flow cytometry study. Eur. Heart J.24(19), 1744–1749 (2003).
   PubMed Web of Science ®Google Scholar
• Saw J, Steinhubl SR, Berger PB et al. Lack of adverse clopidogrel–atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation108(8), 921–924 (2003).
   PubMed Web of Science ®Google Scholar
• Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation109(11), 1335–1338 (2004).
   PubMed Web of Science ®Google Scholar
• Saw J, Brennan DM, Steinhubl SR et al. Lack of evidence of a clopidogrel–statin interaction in the CHARISMA trial. J. Am. Coll. Cardiol.50(4), 291–295 (2007).
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart96(3), 186–189 (2010).
   PubMed Web of Science ®Google Scholar
• Harmsze AM, Robijns K, van Werkum JW et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb. Haemost.103(5), 920–925 (2010).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J. Am. Coll. Cardiol.52(19), 1557–1563 (2008).
   PubMed Web of Science ®Google Scholar
• Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of antiplatelet drug resistance. Clin. Genet.75(1), 1–18 (2009).
   PubMed Web of Science ®Google Scholar
• Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br. J. Clin. Pharmacol.66(2), 222–232 (2008).
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360(4), 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Sugunaraj JP, Palaniswamy C, Selvaraj DR, Chaitanya Arudra SK, Sukhija R. Clopidogrel resistance. Am. J. Ther.17(2), 210–215 (2010).
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet373(9660), 309–317 (2009).
   PubMed Web of Science ®Google Scholar
• Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation111(16), 2099–2106 (2005).
   PubMed Web of Science ®Google Scholar
• Seip RL, Duconge J, Ruano G. Implementing genotype-guided antithrombotic therapy. Future Cardiol.6(3), 409–424 (2010).
   PubMedGoogle Scholar
• Michelson AD, Cattaneo M, Eikelboom JW et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost.3(6), 1309–1311 (2005).
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J. Am. Coll. Cardiol.51(19), 1829–1843 (2008).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract. Res. Clin. Endocrinol. Metab.23(3), 375–388 (2009).
   PubMed Web of Science ®Google Scholar
• Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb. Haemost.101(1), 151–156 (2009).
   PubMed Web of Science ®Google Scholar
• Gaborit B, Frere C, Cuisset T, Alessi MC, Dutour A. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. J. Thromb. Haemost.7(11), 1939–1941 (2009).
   PubMed Web of Science ®Google Scholar
• Pamukcu B, Oflaz H, Onur I et al. Relationship between the serum sCD40L level and aspirin-resistant platelet aggregation in patients with stable coronary artery disease. Circ. J.72(1), 61–66 (2008).
   PubMed Web of Science ®Google Scholar
• Erlinge D, Varenhorst C, Braun OO et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J. Am. Coll. Cardiol.52(24), 1968–1977 (2008).
   PubMed Web of Science ®Google Scholar
• Simon DI, Schmaier AH. Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. J. Am. Coll. Cardiol.50(16), 1548–1550 (2007).
   PubMed Web of Science ®Google Scholar
• Watala C, Pluta J, Golanski J et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J. Mol. Med.83(2), 148–158 (2005).
   PubMed Web of Science ®Google Scholar
• Michelson AD, Frelinger AL 3rd, Furman MI. Current options in platelet function testing. Am. J. Cardiol.98(10A), 4N-10N (2006).
   Google Scholar
• Ohmori T, Yatomi Y, Nonaka T et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost.4(6), 1271–1278 (2006).
   PubMed Web of Science ®Google Scholar
• Harrison P KD. Laboratory monitoring of antiplatelet therapy. In: Platelets in Hematologic and Cardiovascular Disorders – A Clinical Handbook. Gresele P, Fuster V, Lopez J, Page C, Vermylen J (Eds). Cambridge University Press, Cambridge, UK, 386–407 (2008).
   Google Scholar
• Favaloro EJ. Clinical utility of the PFA-100. Semin. Thromb. Hemost.34(8), 709–733 (2008).
   PubMed Web of Science ®Google Scholar
• Harrison P KD. Clinical tests of platelet function. In: Platelets. Michelson A (Ed.). Elsevier Inc./Academic Press, CA, USA, 445–474 (2007).
   Google Scholar
• Velik-Salchner C, Maier S, Innerhofer P et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth. Analg.107(6), 1798–1806 (2008).
   PubMed Web of Science ®Google Scholar
• Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb. Res.71(5), 397–403 (1993).
   PubMed Web of Science ®Google Scholar
• Gengo FM, Rainka M, Robson M et al. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J. Clin. Pharmacol.48(3), 335–343 (2008).
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med.167(15), 1593–1599 (2007).
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ336(7637), 195–198 (2008).
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J.154(2), 221–231 (2007).
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol.51(14), 1404–1411 (2008).
   PubMed Web of Science ®Google Scholar
• Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am. Heart J.153(2), 175–181 (2007).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ324(7329), 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Gladding P, Webster M, Zeng I et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc. Interv.1(6), 620–627 (2008).
   PubMed Web of Science ®Google Scholar
• Lev EI, Patel RT, Maresh KJ et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J. Am. Coll. Cardiol.47(1), 27–33 (2006).
   PubMed Web of Science ®Google Scholar
• Milicic D, Skoric B, Lovric D. Drug-specific thienopyridine resistance in patient with recurrent coronary stent thrombosis. J. Invasive Cardiol.21(8), E157–E160 (2009).
   Google Scholar
• Campo G, Valgimigli M, Gemmati D et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J. Am. Coll. Cardiol.50(12), 1132–1137 (2007).
   PubMed Web of Science ®Google Scholar
• Gladding P, Webster M, Ormiston J, Olsen S, White H. Antiplatelet drug nonresponsiveness. Am. Heart J.155(4), 591–599 (2008).
   PubMed Web of Science ®Google Scholar
• Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am. J. Cardiol.101(7), 1060–1063 (2008).
   PubMed Web of Science ®Google Scholar
• Schroeder WS, Ghobrial L, Gandhi PJ. Possible mechanisms of drug-induced aspirin and clopidogrel resistance. J. Thromb. Thrombolysis22(2), 139–150 (2006).
   PubMed Web of Science ®Google Scholar
• Neubauer H, Engelhardt A, Kruger JC et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel – a whole blood aggregometry study following coronary stenting. J. Cardiovasc. Pharmacol.56(1), 91–97 (2010).
   PubMed Web of Science ®Google Scholar
• Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch. Intern. Med.170(8), 704–710 (2010).
   PubMed Web of Science ®Google Scholar
• Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation122(24), 2619–2633 (2010).
   PubMed Web of Science ®Google Scholar
• Bhindi R, Ormerod O, Newton J, Banning AP, Testa L. Interaction between statins and clopidogrel: is there anything clinically relevant? QJM101(12), 915–925 (2008).
   PubMed Web of Science ®Google Scholar
• Berger PB, Bhatt DL, Fuster V et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation121(23), 2575–2583 (2010).
   PubMed Web of Science ®Google Scholar
• Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb. Res.63(6), 587–593 (1991).
   PubMed Web of Science ®Google Scholar
• Helgason CM, Tortorice KL, Winkler SR et al. Aspirin response and failure in cerebral infarction. Stroke24(3), 345–350 (1993).
   PubMed Web of Science ®Google Scholar
• Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke34(4), 849–854 (2003).
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke35(1), 175–178 (2004).
   PubMed Web of Science ®Google Scholar
• Macchi L, Petit E, Brizard A, Gil R, Neau JP. Aspirin resistance in vitro and hypertension in stroke patients. J. Thromb. Haemost.2(11), 2051–2053 (2004).
   PubMed Web of Science ®Google Scholar
• Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke36(5), 1001–1005 (2005).
   PubMed Web of Science ®Google Scholar
• McCabe DJ, Harrison P, Mackie IJ et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets16(5), 269–280 (2005).
   PubMed Web of Science ®Google Scholar
• Berrouschot J, Schwetlick B, von Twickel G et al. Aspirin resistance in secondary stroke prevention. Acta Neurol. Scand.113(1), 31–35 (2006).
   PubMed Web of Science ®Google Scholar
• Hohlfeld T, Weber AA, Junghans U et al. Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc. Dis.24(1), 43–50 (2007).
   PubMed Web of Science ®Google Scholar
• Bennett D, Yan B, Macgregor L, Eccleston D, Davis SM. A pilot study of resistance to aspirin in stroke patients. J. Clin. Neurosci.15(11), 1204–1209 (2008).
   PubMed Web of Science ®Google Scholar
• Englyst NA, Horsfield G, Kwan J, Byrne CD. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J. Cereb. Blood Flow Metab.28(6), 1196–1203 (2008).
   PubMed Web of Science ®Google Scholar
• Seok JI, Joo IS, Yoon JH et al. Can aspirin resistance be clinically predicted in stroke patients? Clin. Neurol. Neurosurg.110(2), 110–116 (2008).
   PubMed Web of Science ®Google Scholar
• Cha JK, Jeon HW, Kang MJ. ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. Eur. J. Neurol.15(12), 1304–1308 (2008).
   PubMed Web of Science ®Google Scholar
• Boncoraglio GB, Bodini A, Brambilla C, Corsini E, Carriero MR, Parati EA. Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. Clin. Neurol. Neurosurg.111(3), 270–273 (2009).
   PubMed Web of Science ®Google Scholar
• Bernstein PL, Jacobson BF, Connor MD, Becker PJ. Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events. J. Neurol. Sci.277(1–2), 80–82 (2009).
   PubMed Web of Science ®Google Scholar
• von Lewinski F, Riggert J, Paulus W. Towards a rationale of platelet aggregation monitoring in stroke prophylaxis? J. Stroke Cerebrovasc. Dis.18(2), 111–115 (2009).
   PubMed Web of Science ®Google Scholar
• Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Eur. J. Neurol.17(3), 434–442 (2010).
   PubMedGoogle Scholar
• Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J. Stroke Cerebrovasc. Dis. DOI: 10.1016/j.jstrokecerebrovasdis.2009.12.004 (2010) (Epub ahead of print).
   Google Scholar
• Tousoulis D, Siasos G, Stefanadis C. Aspirin resistance: what the cardiologist needs to know? Int. J. Cardiol.132(2), 153–156 (2009).
   PubMed Web of Science ®Google Scholar
• Seegmiller A, Sarode R. Laboratory evaluation of platelet function. Hematol. Oncol. Clin. North Am.21(4), 731–742, vii (2007).
   PubMed Web of Science ®Google Scholar